On March 11, the U.S. Food and Drug Administration (FDA) allowed marketing of the first device as a preventative treatment for migraine headaches. This is also the first transcutaneous electrical nerve stimulation device specifically authorized for use before the onset of pain. Read more.
FDA allows marketing of first device to prevent migraine headaches
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
